Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • inlfliximab

    - PMLiVE

    Sandoz launches first and only multiple sclerosis biosimilar in US

    The treatment is FDA-approved to treat MS and Crohn’s disease

    - PMLiVE

    Sandoz biosimilar receives EC approval to treat MS

    Tyruko is the first and only biosimilar treatment for relapsing-remitting MS in Europe

    - PMLiVE

    Amgen announces positive results for Solaris biosimilar for paroxysmal nocturnal haemoglobinuria

    ABP 959 demonstrated no ‘clinically meaningful’ difference to the reference product in the phase 3 study

    EU flag

    EMA accepts Mundipharma’s application for invasive candidiasis treatment rezafungin

    Despite currently available treatments, the mortality rate for patients with invasive candidiasis remains high at up to 40%

    - PMLiVE

    FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

    Cimerli belongs to the anti-VEGF therapy class of biologics that has helped retinal patients maintain or gain vision

    - PMLiVE

    Sandoz’s application for MS biosimilar accepted by FDA

    The proposed ‘first-of-a-kind’ biosimilar matched the reference medicine, Biogen’s Tysabri, in terms of efficacy, safety and immunogenicity

    - PMLiVE

    J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

    In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a bid to protect Remicade

    - PMLiVE

    The US celebrates five years of biosimilars on the market – a look to the past, present and future

    Why the success of biosimilars in the US has been mixed

    - PMLiVE

    Sandoz finally wins FDA approval for Neulasta biosimilar

    Follows a three year wait since initial rejection in 2016

    Novartis building

    Novartis expands its generics franchise with natalizumab biosimilar

    Says affordability is a challenge to access

    Roche Basel Switzerland

    New products help lift Roche outlook despite biosimilar onslaught

    Two new cancer therapies approved in Q2

    - PMLiVE

    Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

    Will launch Herzuma in seven European countries including the UK and Germany

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links